Results of Infrapopliteal Endovascular Procedures Performed in Diabetic Patients with Critical Limb Ischemia and Tissue Loss from
the Perspective of an Angiosome-Oriented Revascularization Strategy
Table 6
TASC-II classification for the worst lesion treated and perioperative data according to the patent tibial vessels achieved to the foot.
Perioperative data
value
Runoff 0 ()
Runoff 1 ()
Runoff > 1 ()
Runoff > 1 versus runoff 1
Runoff > 1 versus runoff 0
Runoff 1 versus runoff 0
TASC-B
0 (0%)
5 (7.8%)
1 (4.8%)
0.63
0.37
0.57
TASC-C
4 (25.0%)
9 (14.1%)
2 (9.5%)
0.72
0.20
0.28
TASC-D
12 (75.0%)
50 (78.1%)
18 (85.7%)
0.54
0.43
0.74
Combined treatment*
9 (56.3%)
25 (39.1%)
11 (52.4%)
0.28
0.81
0.21
Multiple revascularization
6 (11.5%)
28 (53.8%)
18 (34.6%)
0.001
0.005
0.65
Debridement
3 (18.8%)
6 (9.4%)
2 (9.5%)
0.98
0.63
0.37
Minor amputation
6 (37.5%)
19 (29.7%)
3 (14.3%)
0.25
0.13
0.54
Postoperative ABI#
0.52 (0.57–0.66)
0.88 (0.73–0.93)
0.90 (0.77–0.97)
0.54
0.01
0.01
MACE† at 30 days
0 (0%)
3 (4.7%)
0 (0%)
0.57
n.a
0.50
MALE& at 30 days
1 (4.8%)
2 (3.1%)
0 (0%)
0.57
0.56
0.63
Major amputation at 30 days
1 (4.8%)
1 (1.6%)
0 (0%)
0.43
0.56
0.80
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #ABI: ankle-brachial index; †MACE: major adverse cardiovascular event; &MALE: major adverse limb event.
